In paroxysmal noctural hemoglobunria (PNH), therapeutic FD inhibitors were designed to control intravascular hemolysis and prevent C3‐mediated extravascular hemolysis. The gene discussed is C3; the disease is paroxysmal nocturnal hemoglobinuria.